15. Aspirina frente a clopidogrel para la antiagregación simple indefinida tras intervencionismo coronario percutáneo

Vicente Piñero Maciá

Vicente Piñero Maciá Cardiología. Complejo Hospitalario Universitario de A Coruña

Palabras clave: Antiagregación, Prevención secundaria, Enfermedad arterial coronaria

Abstract

En el presente artículo se analiza el estudio HOST-EXAM Extended y los distintos aspectos de interés de este ensayo clínico publicado recientemente en la prestigiosa revista estadounidense Circulation, y que se basa en la continuación del HOST-EXAM, que los autores compartieron en 2021 a través de otra prestigiosa revista inglesa, The Lancet.

The present article analyzes the HOST-EXAM Extended study and the aspects which may be of interest from this clinical trial published recently in the prestigious American journal Circulation, being the continuation of HOST-EXAM, that the authors shared in 2021 by means of another prestigious English journal, The Lancet.

Citas

Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. The Lancet. 2021;397(10293):2487-2496. doi:10.1016/S0140-6736(21)01063-1

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419

Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849-1860. doi:10.1016/S0140-6736(09)60503-1

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329-1339. doi:10.1016/S0140-6736(96)09457-3

Pettersen AR, Seljeflot I, Abdelnoor M, Arnesen H. High On‐Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc. 2012;1(3):e000703. doi:10.1161/JAHA.112.000703

Andò G, De Santis GA, Greco A, et al. P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2022;15(22):2239-2249. doi:10.1016/j.jcin.2022.08.009